Fundraising Fox

Franklin Templeton β€” 2026 Investments

8 investments dated 2026 Β· listed companies and verified rows first Β· show all

Astranisastranis.comin𝕏May 2026 Β· $300M

Astranis manufactures small, high-powered geosynchronous satellites equipped with advanced digital processing technology for global telecommunications and connectivity services.

Advanced ManufacturingDeep TechHardwareSpace TechSan Francisco, US

John Gedmark(Founder/CEO)inRyan McLinko(Founder/CTO)in

Co-investorsAndreessen HorowitzBlack FlagBoxGroupCantos VenturesCherubic VenturesCommonweal Ventures+36 more

Cambrian NetworkMay 2026 Β· $6M

Houston, US

JASON CALEY-BRANNIGAN(Executive Officer)BRIAN BERMAN(Executive Officer)SAMUEL GREEN(Executive Officer, Director)

Co-investorsFlow TradersNomad CapitalPaper VenturesPolychain CapitalSelini Capital

Energyenergy.govin𝕏Aug 2026 Β· $750M

The U.S.

EnergyGovTech

Co-investorsWireframe VenturesPrelude VenturesSequoia CapitalT. Rowe Price

Energy Impact Partnersenergyimpactpartners.comin𝕏Aug 2026 Β· $750M

Energy Impact Partners is an investment firm that connects entrepreneurs with large corporations to fund and support companies working on transforming the global economy toward decarbonization.

CleantechClimate TechEnergy

Lindsay Luger(Founder)inHans Kobler(Founder)in

Co-investorsClean Energy VenturesEvergy VenturesJERAMOL SwitchBlindspot Ventures Management CoBreakthrough Energy Ventures+7 more

Impact Partnersimpact-partners.comin𝕏Aug 2026 Β· $750M

Impact Partners is an impact investing firm active since 2007, focused on supporting a more inclusive society.

Impact & Social Good

Co-investorsCDP Venture CapitalAmazon Alexa FundBlindspot Ventures Management CoBreakthrough Energy VenturesEnergy Impact PartnersGigascale Capital+4 more

Lycia Therapeuticslyciatx.comJun 2026 Β· $75M

Lycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation.

BiotechHealthtechSouth San Francisco, US

Aetna Wun Trombley(President and CEO)Amy Bachrodt(Chief Financial Officer)Jeremy S. Caldwell(Executive Officer, Director)Chin Lee(Chief Medical Officer)Steve Staben(Chief Scientific Officer)Sofia Touami(Chief Business Officer)

Co-investorsREDMILEVersant VenturesBAM ElevateHBM Healthcare InvestmentsInvusJanus Henderson Investors+4 more

Polychainpolychain.capitalJun 2026 Β· $6M

Polychain is an investment firm that manages actively managed portfolios of blockchain-based digital assets, focusing on returns from the cryptocurrency sector.

Crypto & Web3

Olaf Carlson-Wee(Founder & CEO)in

Co-investorsA.Capital VenturesAbstract VenturesAndreessen HorowitzBollinger Investment GroupMirana VenturesMoonhill Capital+7 more

TIFINtifin.comin𝕏Aug 2026 Β· $109M

TIFIN builds AI-driven fintech platforms for wealth management, asset management, and insurance, serving home offices, advisors, and end clients.

AI & Machine LearningFintechSaaS

Co-investorsFINTOP CapitalThirdstream PartnersBroadridgeHamilton LaneMotive Partners

Rows marked β€œSEC filing” are inferred from directors named on the company's SEC Form D β€” public regulatory data, not a portfolio list published by the firm.